

Research Center for Innovative Cancer  
Therapy. Kurume University. November 11,  
Fukuoka, Japan

H. 知的財産権の出願・登録状況（予定を含む。）

1. 特許取得  
なし
2. 実用新案登録  
なし
3. その他  
なし

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
<u>Ohtsu A.</u>	Chemotherapy for advanced unresectable gastric cancer.	Kaminishi, M., Takubo, K., Mafune, K.	The Diversity of Gastric Cancer.	Springer	Tokyo	2005	299-309
<u>Sasako M.</u>	The Gastric Cancer Treatment Guideline	Kaminishi, M., Takubo, K., Mafune, K.	The Diversity of Gastric Carcinoma	Springer-Verlag Tokyo	Tokyo	2005	235-241
<u>Sasako M.</u>	Surgical resection of the stomach with lymph node dissection	Fielding, J.W.L., Hallissey, M.R.	Upper Gastrointestinal Surgery	Springer-Verlag	London	2005	335-347

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, <u>Saijo N.</u> and Nishiwaki Y.	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.	J. Clin. Oncol.	24(1)	64-69	2006
Yamamoto, N., <u>Fukuoka, M.</u> , Negoro, S., Nakagawa, K., Saito, H., Matsui, K., Kawahara, M., Senba, H., Takada, Y., Kudoh, S., Nakano, T., Katakami, N., Sugiura, T., Hosoi, T., Ariyoshi, Y. for the West Japan Thoracic Oncology Group.	Randomized phase II study of docetaxel/ cisplatin versus docetaxel/ irinotecan in advanced non-small cell lung cancer: a West Japan Thoracic Oncology Study (WJTOG9803).	Br J Cancer	90	87-92	2004
Kurata, T., Tamura, K., Kaneda, H., Nogami, T., Uejima, H., Asai, G., Nakagawa, K., <u>Fukuoka, M.</u>	Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance	Ann Oncol	15(1)	173-174	2004
Kurata, T., Tamura, K., Yamamoto, N., Nogami, T., Satoh, T., Kaneda, H., Nakagawa, K., <u>Fukuoka, M.</u>	Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer	Br J Cancer	90(11)	2092-2096	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kaneda, H., Tamura, K., Kurata, T., Uejima, H., Nakagawa, K., <u>Fukuoka, M.</u>	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer	Lung Cancer	46 (2)	247-254	2004
Matsui K, Hirashima T, Nitta T, Kobayashi M, Ogata Y, Furukawa M, Kudoh S, Yoshimura N, Mukohara T, Yamauchi S, Shiraishi S, Kamoi H, Negoro S, Takeda K, Nakagawa K, Takada M, Yana T, <u>Fukuoka M.</u>	A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.	Jpn J Clin Oncol	35	181-187	2005
Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudou S, Takada M, Minato Y, <u>Fukuoka M.</u>	Phase II study of weekly paclitaxel for Relapsed and refractory small cell lung cancer.	Anticancer Res	26	777-782	2006
Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, <u>Fukuoka M</u> , Nakagawa K.	Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.	Int J Cancer	118	812-820	2006
Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katho H, Taniguchi N.	Expression of <i>N</i> -Acetylglucosaminyltransferase V is associated with prognosis and histology in non-small cell lung cancers.	Clin Cancer Res	10 (3)	1773-1779	2004
Kikuchi J, Yamazaki K, Kinoshita I, Asahina H, Imura M, Kikuchi E, Konishi J, Shinagawa N, Oki H, <u>Dosaka-Akita H</u> , Nishimura M.	Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.	Jpn J Clin Oncol	34 (9)	505-509	2004
Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H, Yamamoto S, Iwanari H, Hironaka M, Ishikawa Y, Niki T, Sohara Y, Kodama T, Nishimura M, Fukayama M, <u>Dosaka-Akita H</u> , Aburatani H.	Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.	Clin Cancer Res	11 (5)	1776-1785	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Konishi J, Yamazaki K, Kinoshita I, Isobe H, Ogura S, Sekine S, Ishida T, Takashima R, Nakadate M, Nishikawa S, Hattori T, Asahina H, Imura M, Kikuchi E, Kikuchi J, Shinagawa N, Yokouchi H, Munakata M, <u>Dosaka-Akita H</u> , Nishimura M.	Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.	Anticancer Res	25(1B)	435-442	2005
Ishibashi Y, <u>Dosaka-Akita H</u> , Miyoshi E, Shindoh M, Miyamoto M, Kinoshita I, Miyazaki H, Itoh T, Kondo S, Nishimura M, Taniguchi N.	Expression of N-Acetylglucosaminyltransferase V in the Development of Human Esophageal Cancers: Immunohisto-chemical Data from Carcinomas and Nearby Noncancerous Lesions.	Oncology	69(4)	301-310	2005
Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, <u>Dosaka-Akita H</u> .	E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.	Cancer Res	65(23)	10776-10782	2005
Onda T, <u>Yoshikawa H</u> . et al.	Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan clinical oncology group study JCOG0206.	Jpn J Clin Oncol.	34(1)	43-45	2004
Onda T, <u>Yoshikawa H</u> . et al.	Cisplatin, Paclitaxel and Escalating Doses of Doxorubicin (TAP) in Advanced Ovarian Cancer: a Phase I Trial.	Jpn J Clin Oncol.	34(9):	540-546	2004
Yamamoto K, <u>Yoshikawa H</u> . et al.	Pulmonary metastasectomy for uterine cervical cancer: A multivariate analysis.	Ann Thorac Surg	77	1179-1182	2004
Onda T, <u>Yoshikawa H</u> . et al.	Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian Carcinoma; Proposal for Patients Selection.	Br J Cancer	92(6)	1026-1032	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ohara K, <u>Yoshikawa H.</u> et al.	Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors.	Int J Radiat Oncol Biol Phys	64(4)	1179-1182	2006
Tahara M, <u>Ohtsu A,</u> Fujimoto J, et al	Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.	Oncology Report	11	9-15	2004
Sai K, Saeki M, <u>Ohtsu A,</u> et al	<i>UGT1A1</i> haplotypes associated with reduced glucuronidation increased serum bilirubin in irinotecan-administered Japanese patients with cancer.	Clinical Pharmacology & Therapeutics	75	501-515	2004
Shirao K, <u>Ohtsu A,</u> Takada H, et al	Phase II study of S-1 for treatment of metastatic colorectal carcinoma.	Cancer	100	2355-2361	2004
Muto M, <u>Ohtsu A,</u> Yoshida S	Treatment strategies for esophageal stricture before or after chemoradiotherapy for advanced esophageal cancer.	Digestive Endosc	16	S5-S8	2004
Shirao K, Hoff PM, <u>Ohtsu A,</u> et al	Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.	J Clin Oncol	22	3466-3474	2004
Muto M, Nakane M, <u>Ohtsu A,</u> et al	Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites.	Cancer	101	1375-1381	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamao T, Shimada Y, <u>Ohtsu A</u> , et al	Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneal disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG9603 trial.	Jpn J Clin Oncol	34	316-322	2004
Fukushima-Uesaka H, Sai K, <u>Ohtsu A</u> , et al	Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population.	Drug Metabol Pharmacokin	19	320-326	2004
<u>Ohtsu A</u>	Non-surgical treatment for primary gastric lymphoma.	Educational program book. The joint meeting of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology.		77-83	2004
Yoshida M, <u>Ohtsu A</u> , Boku N, et al	Long-term Survival and Prognostic Factors in Patients with Metastatic Gastric Cancer Treated with Chemotherapy in the Japan Clinical Oncology Group (JCOG) Study.	Jpn J Clin Oncol	34	654-659	2004
<u>Ohtsu A</u>	Chemoradiotherapy for esophageal cancer: current status and perspectives.	Int J Clin Oncol	9	444-450	2004
Nagashima F, <u>Ohtsu A</u> , Yoshida S, et al	Japanese nation-wide post marketing survey of S-1 in patients with advanced gastric cancer.	Gastric Cancer	8	6-11	2005
<u>Ohtsu A</u> .	Current status and future prospect of chemotherapy for metastatic gastric cancer: a review.	Gastric Cancer	8	95-102	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yano T, <u>Ohtsu A</u> , et al.	Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer.	Gastrointest Endosc.	62	31-36	2005
<u>Ohtsu A</u> , <u>Sasako M</u> .	Overview of adjuvant therapy for resected gastric cancer: Differences in Japan and the United States	Seminars in Oncology	32 (suppl9)	S101-S104	2005
Takano T, <u>Ohe Y</u> , Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, <u>Tamura T</u> , Kodama T, <u>Saijo N</u> .	Risk factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.	Lung Cancer.	45(1)	93-104	2004
Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, <u>Tamura T</u> , <u>Saijo N</u> , Nishio K.	Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.	Int. J. Cancer.	108(3)	464-72	2004
Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, <u>Tamura T</u> , <u>Saijo N</u> .	Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.	Clin. Cancer Res.	11(15)	5534-8	2005
Sekine I, <u>Tamura T</u> .	Phase 1 clinical trials in oncology.	N. Engl. J. Med.	352(23)	2451-3	2005
Atagi S, Kawahara M, <u>Tamura T</u> , Noda K, Watanabe K, Yokoyama A, Sugiura T, Senba H, Ishikura S, Ikeda H, Ishizuka N, <u>Saijo N</u> .	Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812).	Jpn. J. Clin. Oncol.	35(4)	195-201	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamamoto N, <u>Tamura T</u> , Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, <u>Ohe Y</u> , Kodama T, Shimizu M, Nishio K, Ishizuka N, <u>Saijo N</u> .	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.	J. Clin. Oncol.	23(6)	1061-9	2005
Takahashi T, <u>Sasaki T</u> , et al.	Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer	Pancreas	28(3)	65-69	2004
Kawada K, <u>Sasaki T</u> , et al.	A multicenter and open label clinical trial of zoredronic acid 4mg in patients with hypercalcemia of malignancy.	JJCO	35(1)	28-33	2005
Kamisawa T, <u>Sasaki T</u> , et al.	Thermo-chemo-radiotherapy for advanced gallbladder carcinoma.	Hepato-Gastro enterology	52	1005-1010	2005
<u>Ohe Y</u> , Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, <u>Saijo N</u> , Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y	A phase II study of cisplatin and docetaxel administered as 3 consecutive weekly infusions for advanced non-small cell lung cancer in elderly patients.	Ann Oncol	15	45-50	2004
Sekine I, Nokihara H, Horiike A, Yamamoto N, Kunitoh H, <u>Ohe Y</u> , <u>Tamura T</u> , Kodama T, <u>Saijo N</u> .	Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma.	Br J Cancer	90	1125-1128	2004
Niho S, <u>Ohe Y</u> , Goto K, Ohmatsu H, Matsumoto T, Kubota K, Kakinuma R, Nishiwaki Y.	Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer.	Jpn J Clin Oncol	34	69-73	2004
Sekine I, Yamamoto N, Kunitoh H, <u>Ohe Y</u> , <u>Tamura T</u> , Kodama T, <u>Saijo N</u> .	Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.	Cancer Treat Rev	30	359-368	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takano T, <u>Ohe Y</u> , Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, <u>Tamura T</u> , Kodama T, <u>Saijo N</u> .	Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.	Lung Cancer	45	93-104	2004
Minami H, <u>Ohe Y</u> , Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, <u>Saijo N</u> , Hanada K, Ogata H.	Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?	J Clin Oncol	22	2901-2908	2004
Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, <u>Ohe Y</u> , <u>Tamura T</u> , Kodama T, Sumi M, <u>Saijo N</u> .	Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.	Cancer Sci	95	691-695	2004
<u>Ohe Y</u>	Chemoradiotherapy for lung cancer: current status and perspectives.	Int J Clin Oncol	9	435-443	2004
Ishikura S, <u>Ohe Y</u> , Nihei K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, Nishiwaki Y, Ogino T.	A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III Non-small-cell lung cancer (NSCLC).	Int J Radiat Oncol Biol Phys	61	1117-1122	2005
Takano T, <u>Ohe Y</u> , Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, <u>Tamura T</u> .	Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients with Recurrent Non-Small-Cell Lung Cancer.	J Clin Oncol	23	6829-6837	2005
Takano T, <u>Ohe Y</u> .	Erlotinib in lung cancer	N Engl J Med	353	1739-1741	2005
<u>Ohe Y</u> .	Chemoradiotherapy for lung cancer	Expert Opin Pharmacother	6	2793-2804	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Ohe Y</u> , Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, <u>Fukuoka M</u> , Ariyoshi Y.	Phase I-II Study of Amrubicin and Cisplatin in Previously Untreated Patients with Extensive-Stage Small-Cell Lung Cancer.	Ann Oncol	16	430-436	2005
Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, <u>Ohe Y</u> , <u>Tamura T</u> , Kodama T, Asamura H, <u>Tsuchiya R</u> , Saijo N.	Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.	Lung Cancer	49	217-223	2005
Mori K, Aoyagi K, Ueda T, Danjoh I, Tsubosa Y, Yanagihara K, <u>Matsuno Y</u> , <u>Sasako M</u> , Sakamoto H, Mafune K, Kaminishi M, Yoshida T, Terada M, Sasaki H	Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings.	Biochem. Biophys. Res. Commun.	313	931-937	2004
Oshiro Y, Kusumoto M, <u>Matsuno Y</u> , Asamura H, <u>Tsuchiya R</u> , Terasaki H, Takei H, Maeshima A, Murayama S, Moriyama N	CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients.	Am. J. Roentogenol.	182	87-91	2004
Asamura H, Nakagawa K, <u>Matsuno Y</u> , Suzuki K, Watanabe A, <u>Tsuchiya R</u>	Thymoma needs a new staging system.	Interact. Cardiovasc. Thorac. Surg.	3	163-167	2004
Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, <u>Matsuno Y</u> , Nakamura S, Mori S, Ohashi Y	Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.	Ann. Oncol.	15	825-834	2004
Sekiguchi N, Nishimoto J, Tanimoto K, Kusumoto S, Onishi Y, Watanabe T, Kobayashi Y, Asamura H, Kagami Y, <u>Matsuno Y</u> , Tobinai K	Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan.	Int. J. Hematol.	79	465-471	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Onishi Y, <u>Matsuno Y</u> , Tateishi U, Maeshima AM, Kusumoto M, Terauchi T, Kusumoto S, Sekiguchi N, Tanimoto K, Watanabe T, Kobayashi Y, Tobinai K	Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings.	Int. J. Hematol.	80	43-51	2004
Tateishi U, Muller NL, Johkoh T, Onishi Y, Arai Y, Satake M, <u>Matsuno Y</u> , Tobinai K	Primary mediastinal lymphoma characteristic features of the various histological subtypes on CT.	Comput. Assist Tomogr.	28	782-789	2004
Noguchi M, Minami Y, Iijima T, <u>Matsuno Y</u> .	Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria.	Pathol. Int.	55	8-13	2005
Minami Y, <u>Matsuno Y</u> , Iijima T, Morishita Y, Onizuka M, Sakakibara Y, Noguchi M.	Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis,	Lung Cancer	48	339-348	2005
Nakagawa K, <u>Matsuno Y</u> , Kunitoh H, Maeshima A, Asamura H, <u>Tsuchiya R</u> .	Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.	Chest	128	140-144	2005
Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, <u>Matsuno Y</u> , <u>Tsuchiya R</u> , Kanai Y, Kondo T, Imoto I, Inazawa J, Hirohashi S.	Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathological features.	Clin. Cancer Res.	11	6177-6184	2005
Yoshida Y, Shibata T, Kokubu A, Tsuta K, <u>Matsuno Y</u> , Kanai Y, Asamura H, <u>Tsuchiya R</u> , Hirohashi S.	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.	Lung Cancer	50	1-8	2005
Takahashi F, Tsuta K, <u>Matsuno Y</u> , Takahashi K, Toba M, Sato K, Uekusa T, Izumi H, Nakamura K, Hirose S, Fukuchi Y.	Adenocarcinoma of the thymus: mucinous subtype.	Hum. Pathol.	36	219-223	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Asamura H, Kameya T, <u>Matsuno Y</u> , Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang S-X, Inoue T, Nakagawa K, Tajima K, Nagai K.	Neuroendocrine neolasms of the lung: a prognostic spectrum.	J. Clin. Oncol.	24	70-75	2006
<u>Nagata Y</u> , Takayama K, Matsuo Y, et al.	Clinical outcomes of a Phase I/II study of 48Gy of stereotactic body radiation therapy in 4 fractions for primary lung cancer using a stereotactic body frame.	Int. J. Radiat. Oncol. Biol. Phys.	63(5)	1427-1431	2005
Takayama K, <u>Nagata Y</u> , Negoro Y, et al.	Treatment planning of steraotactic radiotherapy for lung cancer.	Int. J. Radiat. Oncol. Biol. Phys.	61(5)	1565-1571	2005
Yamauchi C, Mitsumori M, <u>Nagata Y</u> , et al.	Bilateral breast-conserving therapy for bilateral breast cancer. Results and consideraton of radiation technique.	Breast Cancer	12	135-139	2005
Etoh T, <u>Sasako M</u> , et al.	Increased DNA Methyltransferase 1(DNMT1) Protein Expression Correlates Significantly with Poorer Tumor Differentiation and Frequent DNA Hypermethylation of Multiple CpGIslands in Gastric Cancers	American Journal of Pathology	164	689-699	2004
Ushijima T, <u>Sasako M</u> .	Focus on gastric cancer	Cancer Cell	5	121-125	2004
Kinoshita T, <u>Sasako M</u> , et al.	Feasibility study of adjuvant chemotherapywith S-1(TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer	Gastric Cancer	7	104-109	2004
Hartgrink, HH, <u>Sasako M</u> , et al.	Extend Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial	Journal of Clinical Oncology	22	2069-2077	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sano T, <u>Sasako M</u> , et al.	Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy - Japan Clinical Oncology Group Study 9501	Journal of Clinical Oncology	22	2767-2773	2004
Degiuli M, <u>Sasako M</u> , et al.	Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial	EJSO	30	303-308	2004
Sayegh ME, <u>Sasako M</u> , et al.	TNM and Japanese staging systems for gastric cancer: how do they coexist?	Gastric Cancer	7	140-148	2004
<u>Sasako M</u> .	Role of surgery in multidisciplinary treatment for solid cancers	Int J Clin Oncol	9	346-351	2004
Katai H, <u>Sasako M</u> , et al.	Gastric cancer surgery in the elderly without operative mortality	Surgical Oncology	13	235-238	2004
Saka M, <u>Sasako M</u> , et al.	Pancreaticoduodenectomy for advanced gastric cancer.	Gastric Cancer	8	1-5	2005
<u>Sasako M</u> .	Clinical trials of surgical treatment of malignant diseases.	Int J Clin Oncol	10	165-170	2005
Katai H, <u>Sasako M</u> , et al.	Risk factors for pancreas-related abscess after total gastrectomy.	Gastric Cancer	8	137-141	2005
Kodera Y, <u>Sasako M</u> , et al.	Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer	British Journal of Surgery	92	1103-1109	2005
Sakurai H, Maeshima A, Watanabe S, Suzuki K, <u>Tsuchiya R</u> , Maeshima AM, <u>Matsuno Y</u> , Asamura H	Grade of stromal invasion in small adenocarcinoma of the lung: Histopathological minimal invasion and prognosis.	Am. J. Surg. Pathol.	28	198-206	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tada H, <u>Tsuchiya R</u> , <u>Ichinose Y</u> , Koike T, Nishizawa N, Nagai K, and Kato H.	A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).	Lung Cancer	43	167-173	2004
Tsuboi M, Kato H, Nagai K, <u>Tsuchiya R</u> , Wada H, Tada H, <u>Ichinose Y</u> , <u>Fukuoka M</u> , and Jiang H.	Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.	Anticancer Drugs	16	1123-1128	2005
<u>Tsuchiya R</u> , Suzuki K, <u>Ichinose Y</u> , Watanabe Y, Yasumitsu T, Ishizuka N, and Kato H.	Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).	J. Thorac. Cardiovasc. Surg.	129	977-983	2005
Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Niho S, Kodama T, <u>Shinkai T</u> , <u>Tamura T</u> , <u>Ohe Y</u> , Kunitoh H, Yamamoto N, Nokihara H, Yoshida K, Sugiura T, Matsui K, <u>Saijo N</u> .	Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.	Br. J. Cancer.	91(4)	659-65	2004
Takigawa N, Segawa Y, Kishino D, Fujiwara K, Tokuda Y, Seki N, <u>Shinkai T</u> , Watanabe Y, Hiraki S, Kozuki T, Gemba K, Tabata M, Kiama K, Ueoka H. and Tanimoto M.	Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.	Cancer Chemother. Pharmacol.	54	230-236	2004
Hotta K, Takigawa N, Kiura K, Tabata M, Uemura S, Ogino A, Uchida A, Beshho A, Segawa Y, <u>Shinkai T</u> , Nogami N, Harita S, Okimoto N, Ueoka H, and Tanimoto M.	Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.	Anticancer Res.	25	2429-2434	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sawada S, Komori E, Nogami N, Beshho A, Segawa Y, <u>Shinkai T</u> , Nakata M, and Yamashita M.	Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition.	Chest	128	1557-1563	2005
<u>Ichnose Y</u> , Nakai Y, Kudoh S, Semba H, Yoshida S, Nukiwa T, Yamamoto H, Yamane Y, and Niitani H.	UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer (NSCLC): A multiinstitutional phase II trial.	Clin. Cancer Res.	10	4369-4373	2004
<u>Ichnose Y</u> , Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, and Niitani H.	S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer. A multiinstitutional phase II trial.	Clin. Cancer Res.	10	7860-7864	2004
Kubota K, Watanabe K, Kunitoh H, Noda K, <u>Ichnose Y</u> , Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, and Niitani H.	Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.	J. Clin. Oncol.	22	254-260	2004
Kato H, <u>Ichnose Y</u> , Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, and Hamajima N.	A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I adenocarcinoma of the lung.	N. Engl. J. Med.	350	1713-1721	2004
Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, Ikeda J, Asoh H, Yamaguchi M, Yoshino I, and <u>Ichnose Y</u> .	Prognostic value of visceral pleural invasion in resected non-small cell lung cancer diagnosed by using a jet stream of saline solution.	J. Thorac. Cardiovasc. Surg.	127	1587-1592	2004
Yoshino I, Yamaguchi M, Okamoto T, Ushijima C, Fukuyama Y, <u>Ichnose Y</u> , and Maehara Y.	Multimodal treatment for resectable epithelial type malignant pleural mesothelioma.	World J. Surg. Oncol.	2	11-15	2004
Okamoto T, Maruyama R, Shoji F, Ikeda J, Miyamoto T, Nakamura T, Asoh H, and <u>Ichnose Y</u> .	Clinical patterns and treatment outcome of elderly patients in clinical stage IB/II non-small cell lung cancer.	J. Surg. Oncol.	87	134-138	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yohena T, Yoshino I, Kitajima M, Uehara T, Kanematsu T, Teruya T, Ikeda J, and <u>Ichinose Y.</u>	Necessity of preoperative screening for brain metastasis in non-small cell lung cancer patients without lymph node metastasis.	Ann. Thorac. Cardiovasc. Surg.	10	347-349	2004
Taron M, <u>Ichinose Y.</u> , Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, and Moran T.	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.	Clin. Cancer Res.	11	5878-5885	2005
Shoji F, Maruyama R, Okamoto T, Wataya H, Nishiyama K, and <u>Ichinose Y.</u>	Malignant schwannoma of the upper mediastinum originating from the vagus nerve.	World J. Surg. Oncol.	3	65-68	2005
Shoji F, Maruyama R, Okamoto T, Ikeda J, Nakamura T, Wataya H, and <u>Ichinose Y.</u>	Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma.	World J. Surg. Oncol.	3	32-35	2005
Rosell R, <u>Ichinose Y.</u> , Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama KI, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, and Sanchez JJ.	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.	Lung Cancer	50	25-33	2005
Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H, and <u>Ichinose Y.</u>	Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.	Eur. J. Cancer	41	1286-1290	2005
Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T, and <u>Ichinose Y.</u>	Long-term survivors in stage IV non-small cell lung cancer.	Lung Cancer	47	85-91	2005
Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, Ikeda J, Aoki Y, Wataya H, Asoh H, and <u>Ichinose Y.</u>	Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.	Jpn. J. Clin. Oncol.	35	433-438	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Maruyama R, Miyamoto T, Shoji F, Okamoto T, Miyake T, and <u>Ichinose Y.</u>	Intrathoracic omental herniation through the esophageal hiatus in a young patient.	Jpn. J. Thorac. Cardiovasc. Surg.	53	452-454	2005
<u>Ichinose Y.</u> , Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H, and Iwamoto N.	UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.	Br. J. Cancer	93	770-773	2005
Nagano J, <u>Ichinose Y.</u> , Asoh H, Ikeda J, Ohshima A, Sudo N, and Kubo C.	A Prospective Japanese Study of the Association between Personality and the Progression of Lung Cancer.	Intern. Med.	45	57-63	2006
Ikeda J, Maruyama R, Okamoto T, Shoji F, Wataya H, and <u>Ichinose Y.</u>	Phase I Study of Amrubicin Hydrochloride and Cisplatin in Patients Previously Treated for Advanced Non-small Cell Lung Cancer.	Jpn. J. Clin. Oncol.	36	12-16	2006

M. Kaminishi  
K. Takubo  
K. Mafune (Eds.)

# The Diversity of Gastric Carcinoma

Pathogenesis, Diagnosis, and Therapy

 Springer

# Chemotherapy for Advanced Unresectable Gastric Cancer

ATSUSHI OHTSU

## Introduction

Gastric cancer is a major health problem in many regions of the world. Despite remarkable improvement in survival as a result of early detection and curative surgery, approximately 50 000 deaths were observed in Japan in 2001 [1]. Unresectable advanced or recurrent gastric cancer still has a poor prognosis, with a median survival of less than 9 months. Randomized trials have demonstrated that the 5-fluorouracil (5-FU)-based regimen provides superior survival and quality of life in patients with advanced gastric cancer when compared to best supportive care [2–4]. However, this survival advantage appears to be marginal, and no standard regimens worldwide have yet been established, although various challenges have been conducted.

Recently developed new agents, such as irinotecan, S-1, and taxanes, may have potential to break through this status. Newer-generation regimens with these agents are being investigated in randomized trials worldwide. A molecular targeting agent is another new topic in the field of chemotherapy and is also under development for gastric cancer. This review focuses on the results of newer-generation regimens, particularly in Japan, after a brief summary of older-generation regimens.

## Overview of the Older-Generation Regimens

### *Results from Randomized Controlled Trials*

During the past two decades, various randomized trials (Table 1) have been carried out. In Europe, a combination of fluorouracil, doxorubicin, and high-dose methotrexate (FAMTX) used to be a standard regimen based on the European Organization for Research and Treatment of Cancer (EORTC) trials [5]. However, this regimen failed to demonstrate any superiority to other combination regimens, 5-FU plus cisplatin or etoposide plus 5-FU/leucovorin, in the subsequent EORTC randomized study [6].

TABLE 1. Results of randomized trials using older-generation regimens

Study	Treatment	No. of patients	Response rate (%)	Median survival (months)	P value
Wils et al. (1991) [5]	5-FU + ADM + MMC	103	7	6.7	0.004
	5-FU + ADM + MTX	105	33	9.6	
Kim et al. (1993) [9]	5-FU	94	26	6.9	ns
	5-FU + ADM + MMC	98	25	6.6	
	5-FU + CDDP	103	51	8.5	
Webb et al. (1997) [7]	5-FU + ADM + MTX	130	21	5.7	0.0009
	Epirubicin + CDDP + 5-FU	126	45	8.9	
Vanhoefer et al. (2000) [6]	5-FU + CDDP	134	20	7.2	ns
	Etoposide + LV/5-FU	132	9	7.2	
	5-FU + ADM + MTX	133	12	6.7	
Ohtsu et al. (2003) [10]	5-FU	106	11	7.1	ns
	5-FU + CDDP	104	34	7.3	
	UFT + MMC	70	9	6.0	

5-FU, 5-fluorouracil; ADM, adriamycin; MMC, mitomycin C; MTX, methotrexate; CDDP, cisplatin; LV, leucovorin; UFT, ftorafur and uracil

Another randomized study in the United Kingdom revealed the superiority of a combination of epirubicin, cisplatin (CDDP), and 5-FU (ECF) to FAMTX in terms of survival [7], although survival results of these studies were limited, with a median survival time (MST) ranging from 6 to 8 months. Other trials including 5-FU alone as a control arm and in comparison with FU-based regimens also failed to demonstrate survival prolongation of combination regimens [8,9].

The Japan Clinical Oncology Group (JCOG) has carried out a randomized controlled trial comparing 5-FU alone with UFT (ftorafur and uracil) + mitomycin C (UFTM) and with 5-FU + CDDP (FP) for advanced gastric cancer (JCOG 9205) [10]. A total of 280 patients with advanced gastric cancer were randomly allocated and analyzed for survival, response, and toxicity. At the interim analysis, the UFTM arm showed a significantly inferior survival with higher incidences of hematological toxicities than control arm 5-FU alone, and the registration to UFTM was terminated. Both investigational regimens, FP and UFTM, had a significantly higher incidence of hematological toxicities than 5-FU alone, although they were feasible. The overall response rates of 5-FU alone, FP, and UFTM arms were 11%, 34%, and 9%, respectively. The median progression-free survival was 1.9 months with 5-FU alone, 3.9 months with FP, and 2.4 months with UFTM, respectively. Although FP demonstrated a higher response rate ( $P < 0.001$ ) and longer progression-free survival than 5-FU alone ( $P < 0.001$ ), no differences in overall survival were observed between the arms; the median survival times and 1-year survival rates were 7.1 months and 28% with 5-FU, 7.3 months and 29% with FP, and 6.0 months and 16% with UFTM, respectively. This study concluded that both investigational regimens, FP and UFTM, showed no survival advantages as compared to 5-FU alone, and 5-FU alone still remains a reference arm in future trials for advanced gastric cancer.

Based on the results of these randomized trials, no regimens have exceeded 5-FU alone, and there still remain limitations on efficacy results in older-generation regi-